Mineralys Therapeutics, Inc.(MLYS)
$13.66-0.50 (-3.53%)
MLYS
Mineralys Therapeutics, Inc. hedge funds
$13.66
At close:-0.50 (-3.53%)
Want to see MLYS full AI Analyst Report?
Mineralys Therapeutics, Inc. (MLYS) Hedge Fund Trading Activity
614 Followers
Trend: ▲ Hedge Funds Increased Holdings by 5.4M Shares Last Quarter
Hedge Fund Holdings in MLYS
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
| Woodline Partners LP | New | 100.00% | $24,360,746 | 0.08% | |||
| Added | 4.84% | $155,106,205 | <0.01% | ||||
| RA Capital Management | Not Changed | 0.00% | $193,318,808 | 1.68% | |||
| Deerfield Management Company, LP | Not Changed | 0.00% | $99,464,540 | 1.04% | |||
| Iron Triangle Partners LP | Not Changed | 0.00% | $6,460,546 | 0.74% |
FAQ
Which hedge funds hold Mineralys Therapeutics, Inc.?
The hedge funds that hold the most shares in Mineralys Therapeutics, Inc. are BlackRock, Inc., James E. Flynn and Kevin Molloy.
Are hedge funds buying or selling MLYS?
In the last quarter hedge funds have Increased their holdings in Mineralys Therapeutics, Inc. by 5.4M shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Mineralys Therapeutics, Inc. stock?
Warren Buffet currently does not own shares in Mineralys Therapeutics, Inc..
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here

